ArticleAnnals of medicine2026
Association of hemoglobin level with granulocyte engraftment and red blood cell transfusion by transplant type after hematopoietic stem cell transplantation: a retrospective cohort study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematopoietic stem cell transplantation (HSCT) cures many hematologic malignancies, but peri‑engraftment complications like delayed engraftment and high transfusion requirements remain challenging. Prior studies examined the independent effects of transplant type, hemoglobin, and platelets on post‑transplant outcomes, but whether their associations with these outcomes vary by transplant type is unknown.
methodsIn this retrospective cohort of 341 HSCT patients, we examined whether the associations between pre-transplant hemoglobin and platelet levels and four key peri-engraftment outcomes (RBC transfusion volume, granulocyte engraftment time, megakaryocyte engraftment time, and platelet transfusion requirements) varied by transplant type (allogeneic vs. autologous). Multiple linear regression models for each outcome included diagnosis, transplant type,centered CD34+(C_CD34+),centered prothrombin time (C_PT), centered hemoglobin (C_Hb),and centered platelet (C_PLT) as main effects, with interaction terms: transplant type × C_Hb and transplant type × C_PLT. Bootstrap with 1000 resamples was used to estimate 95% CIs.
resultsThe transplant type × hemoglobin interaction was significant for granulocyte engraftment time (
conclusionsHigher pre‑transplant hemoglobin attenuated the adverse effects of allogeneic HSCT on granulocyte recovery and RBC transfusion requirements, suggesting baseline hemoglobin may serve as a useful risk indicator for peri‑engraftment management in allogeneic recipients, warranting prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.